Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP

AIM: TransCon CNP is a novel prodrug designed to provide sustained release of C‐type natriuretic peptide (CNP) for once‐weekly therapy, addressing the pathology leading to aberrant skeletal development in achondroplasia. This phase 1 trial was initiated to assess the safety, tolerability, pharmacody...

Descripción completa

Detalles Bibliográficos
Autores principales: Breinholt, Vibeke Miller, Mygind, Per Holse, Christoffersen, Eva Dam, Zhang, Ying, Ota, Sho, Will Charlton, R., Viuff, Dorthe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796269/
https://www.ncbi.nlm.nih.gov/pubmed/35481707
http://dx.doi.org/10.1111/bcp.15369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796269/
https://www.ncbi.nlm.nih.gov/pubmed/35481707
http://dx.doi.org/10.1111/bcp.15369

Ejemplares similares